Levi & Korsinsky notifies investors that it has commenced an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) concerning potential violations of the federal securities laws.
On the Q4 2025 earnings call, CEO Adam Grossman stated “ASCENIV achieved $363 million in net revenue, representing 51% year-over-year growth.” Culper Research’s short report contends ASCENIV only achieved its growth on the back of “classic channel stuffing.” ADMA’s annual report further claimed its commercial execution was “expected to accelerate demand utilization while maintaining cost discipline.” Yet, Culper contends that members of ADMA’s distributor attested that “underlying demand ‘is not really growing.’” The gap between the reported 20% revenue growth and the alleged 3% decline represents a substantial divergence. ADMA stock dropped sharply immediately following publication of the short-seller report on March 24, 2026 and throughout the following days.
If you suffered a loss on your ADMA Biologics, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks.
We monitor critical case developments that may affect the price of your shares and your possible monetary recovery.
SnapTrade only shares the tickers you own and your transaction history — not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create an attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery — link your brokerage account with SnapTrade.